Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients

Código QR

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients

Masataka SawakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, JapanAbstract: Anti-HER2 agents, such as trastuzumab, lapatinib, trastuzumab emtansine (T-DM1), and pertuzumab, are standard agents in the treatment of breast cancer overexpressing the human epidermal growth factor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Sawaki M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ab485b74f2304aa78880c777589918a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra DR, et al.
Publicado: (2014)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Laura M. Spring, et al.
Publicado: (2021)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021)

Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy
por: Saeed S. Akhand, et al.
Publicado: (2021)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Matteo Allegretti, et al.
Publicado: (2021)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Lize Wang, et al.
Publicado: (2021)

Role of pertuzumab in the treatment of HER2-positive breast cancer
por: Hubalek M, et al.
Publicado: (2012)

New developments in the treatment of HER2-positive breast cancer
por: Nahta R
Publicado: (2012)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani P, et al.
Publicado: (2015)

Potential of afatinib in the treatment of patients with HER2-positive breast cancer
por: Geuna E, et al.
Publicado: (2012)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno I, et al.
Publicado: (2015)

Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
por: Machado M, et al.
Publicado: (2012)

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
por: Hurvitz SA, et al.
Publicado: (2012)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
por: G. Griguolo, et al.
Publicado: (2021)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
por: Elena I. Kovalenko, et al.
Publicado: (2020)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Ilana Schlam, et al.
Publicado: (2021)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
por: Abdel Kader Y, et al.
Publicado: (2013)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
por: Linehan AS, et al.
Publicado: (2021)

Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
por: Merriam PA, et al.
Publicado: (2011)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Gaia Griguolo, et al.
Publicado: (2021)

De-escalation of radiation therapy in patients with stage I, node-negative, HER2-positive breast cancer
por: Jose G. Bazan, et al.
Publicado: (2021)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
por: Natansh D. Modi, et al.
Publicado: (2021)

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
por: Xavier Pivot, et al.
Publicado: (2017)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem DD, et al.
Publicado: (2014)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Hanne Vos, et al.
Publicado: (2021)

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
por: Costanza Paoletti, et al.
Publicado: (2021)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
por: Lillian M. Smyth, et al.
Publicado: (2021)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Veronica Giusti, et al.
Publicado: (2021)

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies
por: John F. R. Robertson, et al.
Publicado: (2021)

Taxanes in the elderly patient with metastatic breast cancer
por: Yardley DA
Publicado: (2015)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung HT, et al.
Publicado: (2020)

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
por: Twelves C, et al.
Publicado: (2011)

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
por: Laura Pizzuti, et al.
Publicado: (2021)

Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites
por: Soojin Cha, et al.
Publicado: (2021)

Cancer biomarker HER-2/neu in breast cancer in Indian women
por: Singhai R, et al.
Publicado: (2011)

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
por: Yardley DA
Publicado: (2019)

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
por: Puhalla S, et al.
Publicado: (2016)

A Case of Multiple Liver Metastases after Surgery in Elderly HER2-Positive Breast Cancer in Which Anastrozole + Trastuzumab Was Ineffective but T-DM1 Was Effective
por: Tomohiro Shidahara, et al.
Publicado: (2021)

Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis
por: Anders Wilder Erickson, et al.
Publicado: (2021)